Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $57.45 USD
Change Today -0.74 / -1.27%
Volume 183.2K
NEOG On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 4:30 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

neogen corp (NEOG) Snapshot

Open
$58.32
Previous Close
$58.19
Day High
$59.12
Day Low
$56.55
52 Week High
07/22/15 - $62.70
52 Week Low
10/13/14 - $38.74
Market Cap
2.1B
Average Volume 10 Days
381.5K
EPS TTM
$0.91
Shares Outstanding
37.1M
EX-Date
--
P/E TM
63.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOGEN CORP (NEOG)

Related News

No related news articles were found.

neogen corp (NEOG) Related Businessweek News

No Related Businessweek News Found

neogen corp (NEOG) Details

Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products and services for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug and pesticide residues, and general sanitation concerns; and AccuPoint rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors, meat and poultry processors, seafood processors, fruit and vegetable producers, grain producers and processors, and dairies; laboratories; producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products; and various regulatory agencies. The Animal Safety segment provides pharmaceuticals, rodenticides, disinfectants, vaccines, veterinary instruments, topicals, diagnostic products, and genetic testing services to the animal safety market. This segment’s drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm animals and racing animals, such as horses, greyhounds, and camels; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. Its products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. In addition, this segment offers various products for researchers to detect biologically active substances; and proprietary substrates for other diagnostic test kit manufacturers. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.

1,062 Employees
Last Reported Date: 07/30/15
Founded in 1981

neogen corp (NEOG) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $532.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $233.0K
Vice President of Animal Safety
Total Annual Compensation: $213.0K
Vice President of Food Safety
Total Annual Compensation: $194.0K
Compensation as of Fiscal Year 2014.

neogen corp (NEOG) Key Developments

Neogen Corp. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended May 31, 2015

Neogen Corp. reported unaudited consolidated earnings results for the fourth quarter and full year ended May 31, 2015. For the quarter, the company reported total revenue of $78,611,000 compared to $67,262,000 a year ago. Operating income was $14,622,000 compared to $10,991,000 a year ago. Income before tax was $14,308,000 compared to $11,154,000 a year ago. Net income attributable to the company was $9,384,000 or $0.25 per diluted share compared to $7,537,000 or $0.20 per diluted share a year ago. For the year, the company reported total revenue of $283,074,000 compared to $247,405,000 a year ago. Operating income was $53,118,000 compared to $43,391,000 a year ago. Income before tax was $52,076,000 compared to $43,031,000 a year ago. Net income attributable to the company was $33,526,000 or $0.90 per diluted share compared to $28,158,000 or $0.76 per diluted share a year ago. The company generated almost $44 million in cash from operations during the year, now that's double that of a year ago, and used a portion of the cash generated to make investments of $9.6 million in property and equipment and another $6.5 million in acquisitions.

Neogen Corp Seeks Acquisitions

Jim Herbert, Chief Executive Officer of Neogen Corp. (NasdaqGS:NEOG) in Q4 2015 Earnings Call said, "The opportunity for the synergistic acquisitions are continuing to be present. At the moment, we have four good acquisition candidates on the radar screen. It appears that all could be synergistic to both our top and our bottom line. Obviously, we may not get any of these completed but it's sure nice to be looking at these kind of opportunities with a strong balance sheet."

Neogen Introduces New ElELISA Screening Test for Bath Salts

Neogen Corporation has introduced a new ELISA screening test that offers ultrasensitive detection of synthetic cathinones, including methcathinone, methylone and mephedrone, and their metabolites, which are commonly marketed as bath salts, or plant food. Neogen's new simple, sensitive Synthetic Cathinones (Methcathinone) ELISA test kit has been validated for use with whole blood, serum and oral fluid samples, and is compatible with automated and semi-automated instruments. It was developed to require low sample volumes (20 µL), while providing rapid results. Synthetic cathinones are designer drugs chemically synthesized as beta-keto analogs of cathinone, a naturally occurring betaketone amphetamine analog found in the leaves of the khat plant (Catha edulis). Khat has historically been chewed in Middle Eastern and East African countries for its stimulant effects. Synthetic cathinone group members methcathinone and mephedrone were synthesized as early as 1928 and 1929, respectively. This new test is for forensic use only.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEOG:US $57.45 USD -0.74

NEOG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biomerica Inc $0.75 USD 0.00
BioMerieux €107.25 EUR +1.65
IDEXX Laboratories Inc $74.17 USD +1.44
OraSure Technologies Inc $4.96 USD +0.02
Roka Bioscience Inc $3.13 USD +0.01
View Industry Companies
 

Industry Analysis

NEOG

Industry Average

Valuation NEOG Industry Range
Price/Earnings 65.0x
Price/Sales 7.7x
Price/Book 6.2x
Price/Cash Flow 64.5x
TEV/Sales 7.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOGEN CORP, please visit www.neogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.